v3.26.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Reportable Segment Information
Three Months Ended September 30, 2026
TasteHealth & BiosciencesScentTotal
Net sales $687 $566 $689 $1,942 
Cost of sales (419)(305)(392)
Research & development expenses (46)(56)(67)
Selling & administrative expenses (116)(105)(112)
Depreciation expense add-back (a) 22 36 21 
Adjusted Operating EBITDA from Continuing Operations$128 $136 $139 $403 
Reconciliation of Adjusted Operating EBITDA from Continuing Operations:
Total Adjusted Operating EBITDA from Continuing Operations$403 
Depreciation & Amortization(156)
Interest Expense(46)
Other Expense, net (b)(14)
Restructuring and Other Charges (c)(5)
Impairment of Goodwill (d)(23)
Gains (losses) on Business Disposals (e) 2 
Loss on Assets Classified as Held for Sale (f)(236)
Divestiture Costs (g)(10)
Strategic Initiative Costs (h)(9)
Regulatory Costs (i)(34)
Other (l)(6)
Loss from continuing operations before taxes$(134)

Nine Months Ended September 30, 2026
TasteHealth & BiosciencesScentTotal
Net sales $2,055 $1,742 $2,005 $5,802 
Cost of sales (1,227)(927)(1,141)
Research & development expenses (139)(167)(187)
Selling & administrative expenses (344)(324)(321)
Depreciation expense add-back (a) 59 102 58 
Adjusted Operating EBITDA from Continuing Operations$404 $426 $414 $1,244 
Reconciliation of Adjusted Operating EBITDA from Continuing Operations:
Total Adjusted Operating EBITDA from Continuing Operations$1,244 
Depreciation & Amortization(462)
Interest Expense(136)
Other Expense, net (b)(47)
Restructuring and Other Charges (c)(15)
Impairment of Goodwill (d)(23)
Gains (losses) on Business Disposals (e)1 
Loss on Assets Classified as Held for Sale (f)(263)
Divestiture Costs (g)(25)
Strategic Initiative Costs (h)(27)
Regulatory Costs (i)(115)
Entity Realignment Costs (k)(2)
Other (l)(4)
Income from continuing operations before taxes$126 

Three Months Ended September 30, 2025
TasteHealth & BiosciencesScentTotal
Net sales $658 $559 $652 $1,869 
Cost of sales (399)(299)(372)
Research & development expenses (41)(57)(64)
Selling & administrative expenses (112)(101)(107)
Depreciation expense add-back (a) 17 32 18 
Adjusted Operating EBITDA from Continuing Operations$123 $134 $127 $384 
Reconciliation of Adjusted Operating EBITDA from Continuing Operations:
Total Adjusted Operating EBITDA from Continuing Operations$384 
Depreciation & Amortization(151)
Interest Expense(48)
Other Expense, net (b)(13)
Restructuring and Other Charges (c)(14)
Divestiture Costs (g)(11)
Strategic Initiative Costs (h)(10)
Regulatory Costs (i)(7)
Income from continuing operations before taxes$130 
Nine Months Ended September 30, 2025
TasteHealth & BiosciencesScentPharma SolutionsTotal
Net sales $1,962 $1,638 $1,869 $369 $5,838 
Cost of sales (1,190)(875)(1,051)(248)
Research & development expenses (131)(163)(184)(8)
Selling & administrative expenses (321)(294)(298)(42)
Depreciation expense add-back (a) 49 90 50 5 
Adjusted Operating EBITDA from Continuing Operations$369 $396 $386 $76 $1,227 
Reconciliation of Adjusted Operating EBITDA from Continuing Operations:
Total Adjusted Operating EBITDA from Continuing Operations$1,227 
Depreciation & Amortization(439)
Interest Expense(180)
Other Expense, net (b)(52)
Restructuring and Other Charges (c)(49)
Impairment of Goodwill (d)(34)
Gains (losses) on Business Disposals (e)(111)
Gain on Extinguishment of Debt (j)488 
Divestiture Costs (g)(88)
Strategic Initiative Costs (h)(24)
Regulatory Costs (i)(71)
Entity Realignment Costs (k)(5)
Other (l)(6)
Income from continuing operations before taxes$656 
_______________________
a)There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, which is then added back to calculate segment Adjusted Operating EBITDA from continuing operations. This reflects how the CODM reviews Segment results.
b)Please refer to Note 9 for additional information.
c)For 2026 and 2025, represents costs primarily related to severance as part of the IFF Productivity Program.
d)For 2026, represents the impairment of goodwill attributable to the Botanicals & Food Enhancements disposal group. For 2025, represents the impairment of goodwill attributable to the portion of the Food Ingredients reporting unit that is not included within the Food Ingredients or SCL disposal groups.
e)
For 2026, primarily represents gains recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized on the sale of the Nitrocellulose business. Please refer to Note 4 for additional information.
f)For 2026, represents the loss on assets classified as held for sale related to the Botanicals & Food Enhancements disposal group and the CitraSource business.
g)For 2026 and 2025, primarily represents costs related to the Company’s completed and anticipated divestitures, excluding external costs related to the planned divestiture of the Food Ingredients disposal group and the completed divestiture of the SCL disposal group. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.
h)Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization.
i)For 2026 and 2025, represents costs primarily related to provisions recognized for the ongoing investigations of the fragrance businesses and legal fees incurred.
j)
For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of tender offers. Please refer to Note 14 for additional information.
k)For 2026 and 2025, primarily represents consulting costs related to the Company’s implementation of a phased restructuring initiative aimed at optimizing its legal entity framework.
l)For 2026 and 2025, primarily represents the net impact of costs related to severance for certain executives who have separated from the Company. For 2026, also represents losses recognized upon the sale of fixed assets.

Reportable segment capital expenditures consisted as follows:
Three Months Ended September 30,
(DOLLARS IN MILLIONS)20262025
Taste$34 $21 
Health and Biosciences52 39 
Scent 23 21 
Consolidated $109 $81 

Nine Months Ended September 30,
(DOLLARS IN MILLIONS)20262025
Taste$101 $76 
Health and Biosciences149 100 
Scent 92 74 
Pharma Solutions— 38 
Consolidated $342 $288 
Net Sales by Destination of Product Delivery
Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2026202520262025
Europe, Africa and Middle East$690 $688 $2,105 $2,089 
Greater Asia463 441 1,441 1,396 
North America514 493 1,489 1,606 
Latin America275 247 767 747 
Consolidated$1,942 $1,869 $5,802 $5,838 
Three Months Ended September 30,Nine Months Ended September 30,
(DOLLARS IN MILLIONS)2026202520262025
Net sales related to the U.S.$500 $470 $1,417 $1,511 
Net sales attributed to all foreign countries1,442 1,399 4,385 4,327